Although certain rare actinomycetes have been recognized as prolific sources of bioactive natural products, their potential for producing biologically active metabolites still remains unexplored. With the aim of gaining global insights into the genetic background and the metabolic capability of Saccharomonospora azurea SZMC 14600, whole-genome sequencing was performed.
S accharomonospora azurea sp. nov. (synonym Saccharomonospora caesia) is a Gram-positive, soil-dwelling filamentous bacterium (4, 7) belonging to the family Pseudonocardiaceae proposed by Nonomura and Ohara (2) for monosporic actinomycetes. So far, only very limited knowledge exists or is publicly available concerning the relevance of S. azurea to produce biopharmaceutical compounds, e.g., antimicrobials and other active ingredients (3). S. azurea strain SZMC 14600 was selected for whole-genome sequencing based on its ability to (over)produce primycin in combination with a completely uncharacterized selfprotective strategy(ies) The genome sequencing of Saccharomonospora azurea strain SZMC 14600 was performed by combining cycled ligation sequencing on the SOLiD 3Plus system (Life Technologies) with 454 FLX pyrosequencing (Roche). We generated 17,192,716 matepaired (2ϫ 25-bp) and 8,254,794 fragment (50-bp) reads on SOLiD along with 187,566 ϳ400-bp reads on 454 FLX, which altogether yielded Ͼ270-fold coverage. The assembly was performed using the Genomics Workbench 4.8. de novo plug-in and the Omixon Gapped SOLiD Alignment 1.3.2 plug-in (1) provided by CLC Bio and Omixon, respectively, which generated 216 large (Ͼ200-bp) contigs. The automatic annotation of the genome was performed by using the NCBI Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP) (http://www.ncbi.nlm.nih.gov /genomes/static/Pipeline.html), which utilizes GeneMark, Glimmer, and tRNAscan-SE searches. The incomplete draft genome of S. azurea strain SZMC 14600 consists of 4,973,727 bp with a GC content of 70.3%. There are 4,555 putative coding sequences, 47 tRNAs, and 3 rRNA loci.
As the problem of antimicrobial resistance becomes more widespread, the need for new anti-infective agents is more urgent than ever. As a part of these efforts, massively parallel nextgeneration sequencing (NGS) technologies provide tremendous ability to typify microbes not only on the basis of readily observable characteristics but also upon their genetic (biosynthetic) potential (6) . Due to its novel properties, S. azurea strain SZMC 14600 represents an excellent model to support further development of early-stage drug discovery and biopharmaceutical product improvement.
Nucleotide sequence accession numbers. The draft genome sequence of S. azurea strain SZMC 14600 (SZMC, Microbiological Collection of the University of Szeged) has been deposited at DDBJ/EMBL/ GenBank under accession number AHBX00000000. The version described in this paper is the first version, AHBX01000000.
